Month: September 2022

Lloyd-Jones, Guy C.;Butts, Craig P. published 《Nickel(II) complexes bearing (phosphinoaryl)oxazoline ligands as pro-catalysts for Grignard cross-coupling》. The research results were published in《Tetrahedron》 in 1998.Synthetic Route of C25H26NOP The article conveys some information:

Ni(II) complexes bearing chiral (phosphinoaryl)oxazoline ligands, e.g., I, are pro-catalysts for cross-coupling of (Z)-styryl bromide with (1-phenylethyl)magnesium chloride. Under suitable conditions, there is a dynamic kinetic resolution resulting in moderate enantioselectivity. The nature of the substituent at the stereogenic center of the oxazoline ligand affects catalysis in two distinct ways: smaller substituents lead to improved rates and selectivities while polar substituents reverse the sense of asym. induction. The solid state structure of one [(phosphinoaryl)oxazoline]nickel(II) pro-catalyst was determined by single crystal x-ray diffraction. To complete the study, the researchers used (S)-2-(2-(Diphenylphosphanyl)phenyl)-4-isobutyl-4,5-dihydrooxazole (cas: 167693-62-1) .

(S)-2-(2-(Diphenylphosphanyl)phenyl)-4-isobutyl-4,5-dihydrooxazole(cas: 167693-62-1) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.Synthetic Route of C25H26NOP

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Related Products of 34031-32-8In 2021, Wall, Stephanie B.;Li, Rui;Butler, Brittany;Burg, Ashley R.;Tse, Hubert M.;Larson-Casey, Jennifer L.;Carter, A. Brent;Wright, Clyde J.;Rogers, Lynette K.;Tipple, Trent E. published 《Auranofin-mediated NRF2 induction attenuates interleukin 1 beta expression in alveolar macrophages》. 《Antioxidants》published the findings. The article contains the following contents:

Background: Alveolar macrophages (AMs) are resident inflammatory cells in the lung that serve as early sentinels of infection or injury. We have identified thioredoxin reductase 1 inhibition by gold compounds increases activation of nuclear factor erythroid 2-related factor 2 (NRF2)-dependent pathways to attenuate inflammatory responses. The present studies utilized murine alveolar macrophages (MH-S) to test the hypothesis that the gold compound, auranofin (AFN), decreases interleukin (IL)-1β expression through NRF2-mediated interactions with nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway genes and/or increases in glutathione synthesis. Methods: MH-S cells were treated with AFN and lipopolysaccharide (LPS) and analyzed at 6 and 24 h. The Il1b promoter was analyzed by chromatin immunoprecipitation for direct interaction with NRF2. Results: Expression of IL-1β, p-IκBα, p-p65 NF-kB, and NOD-, LRR-, and pyrin domain-containing protein 3 were elevated by LPS exposure, but only IL-1β expression was suppressed by AFN treatment. Both AFN and LPS treatments increased cellular glutathione levels, but attenuation of glutathione synthesis by buthionine sulfoximine (BSO) did not alter expression of Il-1β. Anal. revealed direct NRF2 binding to the Il1b promoter which was enhanced by AFN and inhibited the transcriptional activity of DNA polymerase II. Conclusions: Our data demonstrate that AFN-induced NRF2 activation directly suppresses IL-1β synthesis independent of NFκB and glutathione-mediated antioxidant mechanisms. NRF2 binding to the promoter region of IL1β directly inhibits transcription of the IL1β gene. Collectively, our research suggests that gold compounds elicit NRF2-dependent pulmonary protection by suppressing macrophage-mediated inflammation. And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a gold(I)-phosphine thiolate small molecule described to produce antiinflammatory and antiarthritic effects.Related Products of 34031-32-8

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Rimkus, Audrius;Sewald, Norbert published 《Conjugate addition of organozinc compounds to nitroolefins》. The research results were published in《Synthesis》 in 2004.Recommanded Product: (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine The article conveys some information:

Sym. R¹₂Zn [R¹ = Et, NC(CH₂)₃, EtO₂C(CH₂)₃, etc.] or mixed diorganozinc compounds R¹ZnR² (R¹ = n-Bu, cyclohexyl, n-heptyl, etc.; R² = Me₃SiCH₂) smoothly react with a series of nitroolefins R³CH:CR⁴NO₂ [R³ = Ph, MeO₂C, (MeO)₂CH, R⁴ = H; R³ = EtO₂C, R⁴ = Me, Et] in the presence of catalytic amounts of copper(I) salts to provide synthetically versatile nitro compounds R¹R³CHCHR⁴NO₂ in moderate to good yields without racemization (when R¹ is chiral). Simple alkyl groups, functionalized residues, or mixed trimethylsilylmethyl (TMSM) organozinc compounds may be employed for conjugate addition, while the TMSM group is not being transferred. Ipso-Substitution is observed in absence of the copper(I) salt. Enantiomerically pure copper(I) complexes with BINOL based chiral phosphoramidite ligands efficiently catalyze the addition of dialkylzinc compounds to nitroalkenes. In nitro acrylates, the nitroolefin moiety acts as the more powerful Michael acceptor compared to the acrylate moiety. The products can easily be transformed into β²-homoamino acids, compounds of high relevance for different areas of preparative organic chem. And (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine (cas: 201732-49-2) was used in the research process.

(11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(cas: 201732-49-2) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.Recommanded Product: (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Evans, Andris;Kavanagh, Kevin A. published 《Evaluation of metal-based antimicrobial compounds for the treatment of bacterial pathogens》 in 2021. The article was appeared in 《Journal of Medical Microbiology》. They have made some progress in their research.Name: ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold The article mentions the following:

A review. Antimicrobial resistance (AMR) is one of the greatest global health challenges of modern times and its prevalence is rising worldwide. AMR within bacteria reduces the efficacy of antibiotics and increases both the morbidity and the mortality associ- ated with bacterial infections. Despite this growing risk, few antibiotics with a novel mode of action are being produced, leading to a lack of antibiotics that can effectively treat bacterial infections with AMR. Metals have a history of antibacterial use but upon the discovery of antibiotics, often became overlooked as antibacterial agents. Meanwhile, metal-based complexes have been used as treatments for other diseases, such as the gold-containing drug auranofin, used to treat rheumatoid arthritis. Metal-based antibacterial compounds have novel modes of action that provide an advantage for the treatment of bacterial infections with resistance to conventional antibiotics. In this review, the antibacterial activity, mode of action, and potential for systemic use of a number of metal-based antibacterial complexes are discussed. The current limitations of these compounds are highlighted to determine if metal-based agents are a potential solution for the treatment of bacterial infections, especially those resistant to conventional antibiotics. To complete the study, the researchers used ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) .

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress.Name: ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Formula: C20H36AuO9PS《Inhibition of thioredoxin reductase (TrxR) triggers oxidative stress-induced apoptosis in filarial nematode Setaria cervi channelized through ASK-1-p38 mediated caspase activation》 was published in 2021. The authors were Joardar, Nikhilesh;Sen, Animesh;Rath, Jnanendra;Babu, Santi P. Sinha, and the article was included in《Molecular & Biochemical Parasitology》. The author mentioned the following in the article:

Inhibition of an imperative antioxidant enzyme with subsequent death is a victorious and widely accepted strategy to combat various infectious diseases. Among different antioxidant enzymes, thioredoxin reductase (TrxR) is an exclusive one. Studies have revealed that direct inhibition of TrxR by different classes of chem. moieties promptly results in the death of an organism. Especially the structural as well as biochem. modifications of the enzyme upon inhibition project serious threat towards the subject organism. Herein, an attempt was made to inhibit TrxR of filarial species by administering Auranofin, 1 chloro 2,4 dinitrobenzene (CDNB), Curcumin, and a novel carbamo dithioperoxo(thioate) derivative (4a). Our study has revealed that inhibition of TrxR resulted in the induction of the classical CED pathway of apoptosis along with the intrinsic and extrinsic pathways of apoptosis (Caspase mediated) routed through the ASK-1/p38 axis. Druggability anal. of filarial TrxR for the selected compounds was performed in silico through mol. docking studies. Therefore, this study attempts to decipher the mechanism of apoptosis induction following TrxR inhibition. The safety of those four compounds in terms of dose and toxicity was taken under consideration. Thitherto, the mechanism of TrxR mediated initiation of cell death in filarial parasite has remained undercover, and therefore, it is a maiden report on the characterization of apoptosis induction upon TrxR inhibition which will eventually help in generating effective antifilarial drugs in the future. To complete the study, the researchers used ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) .

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.Formula: C20H36AuO9PS

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Karsa, Mawar;Kosciolek, Angelika;Bongers, Angelika;Mariana, Anna;Failes, Tim;Gifford, Andrew J.;Kees, Ursula R.;Cheung, Laurence C.;Kotecha, Rishi S.;Arndt, Greg M.;Haber, Michelle;Norris, Murray D.;Sutton, Rosemary;Lock, Richard B.;Henderson, Michelle J.;Somers, Klaartje published 《Exploiting the reactive oxygen species imbalance in high-risk pediatric acute lymphoblastic leukemia through auranofin》. The research results were published in《British Journal of Cancer》 in 2021.Safety of ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold The article conveys some information:

The prognosis for high-risk childhood acute leukemias remains dismal and established treatment protocols often cause long-term side effects in survivors. This study aims to identify more effective and safer therapeutics for these patients. A high-throughput phenotypic screen of a library of 3707 approved drugs and pharmacol. active compounds was performed to identify compounds with selective cytotoxicity against leukemia cells followed by further preclin. evaluation in patient-derived xenograft models. Auranofin, an FDA-approved agent for the treatment of rheumatoid arthritis, was identified as exerting selective anti-cancer activity against leukemia cells, including patient-derived xenograft cells from children with high-risk ALL, vs. solid tumor and non-cancerous cells. It induced apoptosis in leukemia cells by increasing reactive oxygen species (ROS) and potentiated the activity of the chemotherapeutic cytarabine against highly aggressive models of infant MLL-rearranged ALL by enhancing DNA damage accumulation. The enhanced sensitivity of leukemia cells towards auranofin was associated with lower basal levels of the antioxidant glutathione and higher baseline ROS levels compared to solid tumor cells. Our study highlights auranofin as a well-tolerated drug candidate for high-risk pediatric leukemias that warrants further preclin. investigation for application in high-risk pediatric and adult acute leukemias. And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase.Safety of ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

COA of Formula: C38H34NO2PIn 1999, Imbos, Rosalinde;Brilman, Mirjan H. G.;Pineschi, Mauro;Feringa, Ben L. published 《Highly Enantioselective Catalytic Conjugate Additions to Cyclohexadienones. [Erratum to document cited in CA131:228499]》. 《Organic Letters》published the findings. The article contains the following contents:

The corrected versions of references 10 and 11 are given. To complete the study, the researchers used (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine (cas: 201732-49-2) .

(11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(cas: 201732-49-2) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.COA of Formula: C38H34NO2P

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Product Details of 34031-32-8In 2021, Kim, Hyun Young;Choi, Young Jae;Kim, Sang Kyum;Kim, Hyunsung;Jun, Dae Won;Yoon, Kyungrok;Kim, Nayoun;Hwang, Jungwook;Kim, Young-Mi;Lim, Sung Chul;Kang, Keon Wook published 《Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome》. 《Communications Biology》published the findings. The article contains the following contents:

Demand for a cure of liver fibrosis is rising with its increasing morbidity and mortality. Therefore, it is an urgent issue to investigate its therapeutic candidates. Liver fibrosis progresses following ‘multi-hit’ processes involving hepatic stellate cells, macrophages, and hepatocytes. The NOD-like receptor protein 3 (NLRP3) inflammasome is emerging as a therapeutic target in liver fibrosis. Previous studies showed that the anti-rheumatic agent auranofin inhibits the NLRP3 inflammasome; thus, this study evaluates the antifibrotic effect of auranofin in vivo and explores the underlying mol. mechanism. The antifibrotic effect of auranofin is assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. Moreover, hepatic stellate cell (HSC), bone marrow-derived macrophage (BMDM), kupffer cell, and hepatocyte are used to examine the underlying mechanism of auranofin. Auranofin potently inhibits activation of the NLRP3 inflammasome in BMDM and kupffer cell. It also reduces the migration of HSC. The underlying mol. mechanism was inhibition of cystine-glutamate antiporter, system Xc. Auranofin inhibits system Xc activity and instantly induced oxidative burst, which mediated inhibition of the NLRP3 inflammasome in macrophages and HSCs. Therefore, to the best of our knowledge, we propose the use of auranofin as an anti-liver fibrotic agent.((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) were involved in the experimental procedure.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a gold(I)-phosphine thiolate small molecule described to produce antiinflammatory and antiarthritic effects.Product Details of 34031-32-8

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Computed Properties of C25H26NOPIn 2002, Fairlamb, Ian J. S.;Lloyd-Jones, Guy C.;Vyskocil, Stepan;Kocovsky, Pavel published 《Analysis of stereochemical convergence in asymmetric Pd-catalysed allylic alkylation reactions complicated by halide and memory effects》. 《Chemistry – A European Journal》published the findings. The article contains the following contents:

A quant. two-term description of memory effects arising in Pd-catalyzed allylic alkylation reactions formally proceeding through ‘meso’-type π-allylpalladium intermediates is presented. The utility of this description (stereochem. convergence (s.c.) and global enantiomeric excess (ee_g)) is demonstrated by application to a series of Pd-catalyzed allylic alkylation reactions involving racemic cyclopentenyl esters. Anal. of such reactions, by employing a range of enantiomerically pure monophosphine ligands, reinforces the conclusion that selectivities (enantiomeric excess (ee) values) obtained under standard ‘benchmark’ type conditions may be very misleading when powerful memory effects are operative. By comparison of s.c. and ee for a given ligand/solvent combination under a range of related conditions, however, one may predict the limiting (‘latent’) selectivity that will be obtained when the memory effect is negated. This technique is exemplified with one particular ligand [I; wherein Z = NMe₂] for which a number of strategies were employed to find conditions that negate the memory effect and reveal the limiting selectivity of the ligand. These conditions give a higher limiting global selectivity than that obtainable by using standard diastereoisomer equilibration methods such as added halide. Thus, the anal. of s.c. vs. ee_g also allows subtle changes in selectivity to be discerned. The difference in limiting selectivity (chloride vs. non-chloride conditions) is proposed to arise through the nucleophilic attack of neutral monodentate vs. cationic bidentate complexes I (wherein Z = NMe₂, OMe). The experimental procedure involved many compounds, such as (S)-2-(2-(Diphenylphosphanyl)phenyl)-4-isobutyl-4,5-dihydrooxazole (cas: 167693-62-1) .

(S)-2-(2-(Diphenylphosphanyl)phenyl)-4-isobutyl-4,5-dihydrooxazole(cas: 167693-62-1) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.Computed Properties of C25H26NOP

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Pereira, Sarah A. P.;Bobbink, Felix D.;Dyson, Paul J.;Saraiva, M. Lucia M. F. S. published 《Automatic evaluation of cyclooxygenase 2 inhibition induced by metal-based anticancer compounds》 in 2021. The article was appeared in 《Journal of Inorganic Biochemistry》. They have made some progress in their research.Computed Properties of C20H36AuO9PS The article mentions the following:

An automatic methodol. based on micro sequential injection anal. coupled to a lab-on-valve system (termed μSIA-LOV) was developed and used to determine the ability of metal-based anticancer compounds to inhibit cyclooxygenase 2 (COX-2) activity. COX-2 may be involved in pathogenesis of cancer and it is overexpressed in several types of solid tumors. Since platinum-based compounds are extensively used in the treatment of cancer, and ruthenium compounds are considered as promising candidates for next generation of non-targeted anticancer drugs, it is interesting to establish whether COX-2 inhibition is relevant to their mode of action. The μSIA-LOV system was optimized and the IC50 values of each compound were calculated All the results present RSD values less than 2.5%. IC50 values of 9.7 ± 0.6μM to 207 ± 3μM were obtained, with the most active inhibitor for COX-2 being rofecoxib with the metal compounds exhibiting IC50 values in the range 13.7 ± 1.6 to 207 ± 3. The results obtained in this work provide significant information about the mechanism of the studied compounds, mostly ruthenium-based compounds, and the role of COX-2 in their mode of action. Moreover, this work confirmed the potential of the μSIA-LOV system as a simple, versatile, robust, and rapid anal. tool for automating the determination of IC50 values of metal-based compounds And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase.Computed Properties of C20H36AuO9PS

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis